Dimenhydrinate
- Atc Codes:A04AD
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Arlevert, Emedyl, Synkapton, Travel-Gum, Travelgum, Vertirosan; Belgium: Paranausine; Bulgaria: Arlevert, Dimenhydrinat; Czech Republic: Travel-Gum; France: Mercalm, Nausicalm; Germany: Arlevert, Dimenhydrinat, RubieMen; Greece: Drimen, Retager, Travelgum, Vertigo-Vomex; Ireland: Arlevert; Italy: Dimenidr, Lomarin, Travelgum, Valontan, Xamamina; Latvia: Vertirosan; Luxembourg: Dramamine, Paranausine, Vagomine; Malta: Biodramina; Netherlands: Arlevert; Poland: Arlevert, Aviomarin; Portugal: Draminal, Enjomin, Viabom, Vomidrine; Romania: Arlevert; Slovakia: Arlevert; Slovenia: Arlevert, Dramina; Spain: Biodramina, Cinfamar, Saldeva, Salvarina, Travel Well; Sweden: Amosyt, Arlevert, Calma.
North America
Canada: Children’s Motion Sickness Liquid, Dinate, Dimenate, Dimenhydrinate, Gravergol, Gravol, Motion Sickness, Nauseatol, Travel Tabs; USA: Dimenhydrinate.
Latin America
Argentina: Agirax, Dr. Amin, Dramamine, Vertigmine; Brazil: Dramamine, Dramin, Nausilon, Neodrin; Mexico: Apo-Mina, Bomine, Dimicaps, Dramamine, Dramit-GB, Vomisin.
Asia
Japan: Dramamine.
Drug combinations
Dimenhydrinate and Acetaminophen
Dimenhydrinate and Cinnarizine
Chemistry
Dimenhydrinate: C~17~H~21~NO C~7~H~7~ClN~4~O~2~. Mw: 469.96. (1) 1H-Purine-2,6-dione, 8-chloro-3,7-dihydro-1,3-dimethyl-, compd. with 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1); (2) 8-Chlorotheophylline, compound with 2-(diphenylmethoxy)-N,N-dimethylethylamine (1:1).
Pharmacologic Category
Antiemetics; Antihistamines; Histamine H~1~ Antagonist. (ATC-Code: A04AD).
Mechanism of action
Competes with histamine for H~1~-receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract. Blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity.
Therapeutic use
Treatment and prevention of nausea, vertigo, and vomiting associated with motion sickness.
Pregnancy and lactiation implications
Unlabeled use
Treatment of Meniere’s disease.
Contraindications
Hypersensitivity to dimenhydrinate or any component.
Warnings and precautions
May cause CNS depression. Use with caution in cardiovascular disease, increased intraocular pressure or angle-closure glaucoma, prostatic hyperplasia and/or GU obstruction, pyloroduodenal obstruction (including stenotic peptic ulcer) or thyroid dysfunction. Effects may be potentiated when used with other sedative drugs or ethanol. Caution in the elderly. May cause excitation in young children. The I.M. formulation can be used for I.V. administration only after dilution. Some products may contain phenylalanine or tartrazine.